Show Summary Details
Page of

Memantine for Alzheimer’s Disease 

Memantine for Alzheimer’s Disease
Chapter:
Memantine for Alzheimer’s Disease
Author(s):

Joshua Lovinger

DOI:
10.1093/med/9780199377527.003.0002
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 15 September 2019

This chapter provides a summary of a landmark study in behavioral neurology. Is there clinical benefit to initiation of memantine in patients with moderate to severe Alzheimer’s disease already on donepezil? Starting with that question, it describes the basics of the study, including funding, study location, who was studied, how many patients, study design, study intervention, follow-up, endpoints, results, and criticism and limitations. In patients with severe Alzheimer’s disease on a stable dose of donepezil, the addition of memantine was better than placebo in improving cognitive outcomes and decreasing rate of functional decline. The chapter briefly reviews other relevant studies and information, and concludes with a relevant clinical case.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.